Cargando…

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews

BACKGROUND: Adjuvant immunotherapy is revolutionising care for patients with resected stage III and IV melanoma. However, immunotherapy may be associated with toxicity, making treatment decisions complicated. This study aimed to identify factors physicians and nurses considered regarding adjuvant im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Livingstone, Ann, Dempsey, Kathy, Stockler, Martin R., Howard, Kirsten, Long, Georgina V., Carlino, Matteo S., Menzies, Alexander M., Morton, Rachael L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434723/ https://www.ncbi.nlm.nih.gov/pubmed/34507552 http://dx.doi.org/10.1186/s12885-021-08752-1

Ejemplares similares

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
por: Livingstone, Ann, et al.
Publicado: (2023)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines
por: Agarwal, Anupriya, et al.
Publicado: (2021)

Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians’ perspectives and models of care
por: Rychetnik, Lucie, et al.
Publicado: (2012)

Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile
por: Ikeguchi, Alexandra, et al.
Publicado: (2020)

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Māori patients' experiences and perspectives of chronic kidney disease: a New Zealand qualitative interview study
por: Walker, Rachael C, et al.
Publicado: (2017)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

Patient and caregiver preferences for home dialysis—the home first study: a protocol for qualitative interviews and discrete choice experiments
por: Walker, Rachael C, et al.
Publicado: (2015)

Physician’s recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy
por: Nam, Young-Hee, et al.
Publicado: (2017)

Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
por: Kähler, Katharina C., et al.
Publicado: (2018)

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)

Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review
por: El Shayeb, Mohamed, et al.
Publicado: (2012)

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
por: Hauschild, A.
Publicado: (2009)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

Adjuvant effect of IRES-based single-stranded RNA on melanoma immunotherapy
por: Kwak, Hye Won, et al.
Publicado: (2022)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study
por: Li, Tong, et al.
Publicado: (2022)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Factors associated with the use of adjuvant radiation therapy in stage III melanoma
por: King, Amber L. O., et al.
Publicado: (2023)

Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol
por: Dieng, Mbathio, et al.
Publicado: (2020)

Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study
por: Dempsey, Kathy, et al.
Publicado: (2022)

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma
por: Derks, S.H.A.E., et al.
Publicado: (2022)

IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
por: Fukuda, Keitaro
Publicado: (2023)

Dabrafenib and its potential for the treatment of metastatic melanoma
por: Menzies, Alexander M, et al.
Publicado: (2012)

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
por: Goodman, Rachel S., et al.
Publicado: (2023)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Recommended by Physicians
Publicado: (1863)

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
por: Bhave, Prachi, et al.
Publicado: (2020)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Immunotherapy for Non-melanoma Skin Cancer
por: Shalhout, Sophia Z., et al.
Publicado: (2021)

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
por: Menzies, Alexander M., et al.
Publicado: (2014)

US Physicians’ and Nurses’ Motivations, Barriers, and Recommendations for Correcting Health Misinformation on Social Media: Qualitative Interview Study
por: Bautista, John Robert, et al.
Publicado: (2021)

Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG
por: van den Boorn, Jasper G., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bqigo6eq8ljl0t9t5mmaca3p41